The antidepressant fluvoxamine appears to prevent COVID-19 infections from worsening and may help keep patients out of the hospital, a trial based on research from the University of Virginia School of Medicine suggests.
Fluvoxamine is a class of drugs called selective serotonin reuptake inhibitors (SSRIs) that interact with sigma-1 protein in the body and help minimize inflammation. It is commonly used to treat anxiety, depression and obsessive-compulsive disorder (OCD). This drug was found to help reduce inflammation and sepsis in animals by blocking IL-6, a pro-inflammatory cytokine. Fluvoxamine can be useful in the prevention and hospitalization of serious symptoms of COVID-19. The researchers expect to start large-scale trials soon and involve patients from around the world.
To learn more visit the source